| Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms MC Rodriguez-Oroz, M Jahanshahi, P Krack, I Litvan, R Macias, E Bezard, ... The Lancet Neurology 8 (12), 1128-1139, 2009 | 1146 | 2009 |
| Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy JA Obeso, M Stamelou, CG Goetz, W Poewe, AE Lang, D Weintraub, ... Movement disorders 32 (9), 1264-1310, 2017 | 973 | 2017 |
| A brain–spine interface alleviating gait deficits after spinal cord injury in primates M Capogrosso, T Milekovic, D Borton, F Wagner, EM Moraud, ... Nature 539 (7628), 284-288, 2016 | 732 | 2016 |
| Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys A Recasens, B Dehay, J Bové, I Carballo‐Carbajal, S Dovero, ... Annals of neurology 75 (3), 351-362, 2014 | 728 | 2014 |
| Pathophysiology of levodopa-induced dyskinesia: potential for new therapies E Bezard, JM Brotchie, CE Gross Nature Reviews Neuroscience 2 (8), 577-588, 2001 | 664 | 2001 |
| Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque … E Bezard, S Dovero, C Prunier, P Ravenscroft, S Chalon, D Guilloteau, ... Journal of Neuroscience 21 (17), 6853-6861, 2001 | 596 | 2001 |
| Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations B Dehay, M Bourdenx, P Gorry, S Przedborski, M Vila, S Hunot, ... The Lancet Neurology 14 (8), 855-866, 2015 | 573 | 2015 |
| Priorities in Parkinson's disease research WG Meissner, M Frasier, T Gasser, CG Goetz, A Lozano, P Piccini, ... Nature reviews Drug discovery 10 (5), 377-393, 2011 | 539 | 2011 |
| Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease MF Bastide, WG Meissner, B Picconi, S Fasano, PO Fernagut, M Feyder, ... Progress in neurobiology 132, 96-168, 2015 | 528 | 2015 |
| Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing B Boland, WH Yu, O Corti, B Mollereau, A Henriques, E Bezard, ... Nature reviews Drug discovery 17 (9), 660-688, 2018 | 489 | 2018 |
| Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives AHV Schapira, CW Olanow, JT Greenamyre, E Bezard The Lancet 384 (9942), 545-555, 2014 | 474 | 2014 |
| Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia I Aubert, C Guigoni, K Håkansson, Q Li, S Dovero, N Barthe, BH Bioulac, ... Annals of Neurology: Official Journal of the American Neurological …, 2005 | 465 | 2005 |
| Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function E Bézard, S Ferry, U Mach, H Stark, L Leriche, T Boraud, C Gross, ... Nature medicine 9 (6), 762-767, 2003 | 457 | 2003 |
| Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders V Voon, PO Fernagut, J Wickens, C Baunez, M Rodriguez, N Pavon, ... The Lancet Neurology 8 (12), 1140-1149, 2009 | 444 | 2009 |
| The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders P Sokoloff, J Diaz, BL Foll, O Guillin, L Leriche, E Bezard, C Gross CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2006 | 429 | 2006 |
| Presymptomatic compensation in Parkinson's disease is not dopamine-mediated E Bezard, CE Gross, JM Brotchie Trends in neurosciences 26 (4), 215-221, 2003 | 421 | 2003 |
| Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration B Dehay, A Ramirez, M Martinez-Vicente, C Perier, MH Canron, ... Proceedings of the National Academy of Sciences 109 (24), 9611-9616, 2012 | 410 | 2012 |
| Novel pharmacological targets for the treatment of Parkinson's disease AHV Schapira, E Bezard, J Brotchie, F Calon, GL Collingridge, B Ferger, ... Nature reviews Drug discovery 5 (10), 845-854, 2006 | 392 | 2006 |
| Spatiotemporal neuromodulation therapies engaging muscle synergies improve motor control after spinal cord injury N Wenger, EM Moraud, J Gandar, P Musienko, M Capogrosso, L Baud, ... Nature medicine 22 (2), 138-145, 2016 | 390 | 2016 |
| Lysosomal impairment in Parkinson's disease B Dehay, M Martinez‐Vicente, GA Caldwell, KA Caldwell, Z Yue, ... Movement Disorders 28 (6), 725-732, 2013 | 371 | 2013 |
Benjamin DEHAYInstitute of Neurodegnerative DiseasesVerified email at u-bordeaux.fr